This tool specifically predicts outcomes when switching a factor VIII patient from Kovaltry, an unmodified, full-length, standard-half-life recombinant factor VIII (FVIII) concentrate to Jivi, a conjugated 60-kDa branched polyethylene glycol (PEG) extended half-life molecule.
Prior to the Switching Tool’s development, the WAPPS-Hemo team collaborated with hemophilia treaters, and other relevant stakeholders to discuss the value of creating a “switch” algorithm as an aid for the treaters when they are considering a patient switch from Kovaltry to Jivi. Based upon algorithms created by the WAPPS-Hemo team for a recent study, we derived and validated a population PK approach to estimate the future half-life of Jivi on patients currently on Kovaltry.
The Switching Tool flows seamlessly within the operation of WAPPS. Only centres with existing Kovaltry patients will have access to the tool and once accessed, you can simulate outcomes by adjusting dose, frequency, or both, and see the results of the two drugs side by side. Ultimately, new treatment plans can be saved within the program for future reference and use.
We have a demonstration video and an updated user manual that will be released in 7-10 days, so check back to get the complete picture of the features and benefits of the Switching Tool.